This approval is for a globally integrated biotechnology company dedicated to developing innovative cancer treatments. They required bridge funding to their equity raise. The company had equipment located at their US facility and United was able to use the appraised value of their assets to secure a sale leaseback credit facility. The use of the debt proceeds would fund the US facility's operational expenses while the parent entity worked on closing a large equity raise. United Capital Partners worked with its Investor that specializes in growth capital secured by hard assets to provide the approval. An additional wrinkle in the credit profile was the overseas ownership of the borrower, however UCP was able to work around this issue without problems.